Treatment of HCC with Lenvatinib or Regorafenib in combination with Cdk5 inhibition – a new promising therapeutic approach to improve the situation of HCC patients

Petra Huber-Cantonati; L. Kraus; M. A. Ardelt; J. Pachmayr

Treatment of HCC with Lenvatinib or Regorafenib in combination with Cdk5 inhibition – a new promising therapeutic approach to improve the situation of HCC patients

Petra Huber-Cantonati, L. Kraus, M. A. Ardelt, J. Pachmayr

Insitute of Pharmacy

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - 2021
Event	DPhG Annual Meeting - Virtual Meeting , Germany Duration: 28 Sept 2021 → 1 Oct 2021

Conference with scientific content

Conference with scientific content	DPhG Annual Meeting
Country/Territory	Germany
City	Virtual Meeting
Period	28/09/21 → 1/10/21

1 Abstract

Treatment of HCC with Lenvatinib or Regorafenib in combination with Cdk5 inhibition – a new promising therapeutic approach to improve the situation of HCC patients
Huber-Cantonati, P., Kraus, L., Ardelt, M. A. & Pachmayr, J., 2021.
Research output: Contribution to conference › Abstract

Cite this

@conference{f65a933c52d54f3d8607a8ec62ac36dc,

title = "Treatment of HCC with Lenvatinib or Regorafenib in combination with Cdk5 inhibition – a new promising therapeutic approach to improve the situation of HCC patients",

author = "Petra Huber-Cantonati and L. Kraus and Ardelt, {M. A.} and J. Pachmayr",

year = "2021",

language = "English",

note = "DPhG Annual Meeting ; Conference date: 28-09-2021 Through 01-10-2021",

}

TY - CONF

T1 - Treatment of HCC with Lenvatinib or Regorafenib in combination with Cdk5 inhibition – a new promising therapeutic approach to improve the situation of HCC patients

AU - Huber-Cantonati, Petra

AU - Kraus, L.

AU - Ardelt, M. A.

AU - Pachmayr, J.

PY - 2021

Y1 - 2021

M3 - Poster

T2 - DPhG Annual Meeting

Y2 - 28 September 2021 through 1 October 2021

ER -